Treatment of kidney transplant recipients with acei/arb and risk of respiratory tract cancer: A collaborative transplant study report

American Journal of Transplantation

Volumn 11, Issue 11, 2011, Pages 2483-2489

  Opelz, G ^a   Dohler B ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

ACEi; ARB; Cancer; Kidney transplant; Smoking

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER RISK; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; RESPIRATORY TRACT CANCER; RISK ASSESSMENT; SIDE EFFECT; SMOKING; THORAX CANCER;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RESPIRATORY TRACT NEOPLASMS; SMOKING;

EID: 84856469186     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03681.x     Document Type: Article

References (18)

1. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials. Lancet Oncol 2010; 11: 627-636.
2. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: Network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials. Lancet Oncol 2011; 12: 65-82.
3. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
4. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003. (Pubitemid 34286536)
5. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003; 362: 759-766. (Pubitemid 37093915)
6. University of Heidelberg: Collaborative Transplant Study. [cited 2011 March 1]; Available from: Http://www.ctstransplant.org.
7. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80: 254-264.
8. Kasiske BL, Snyder JJ, Gilbertson DT,Wang C. Cancer after kidney transplantation in the United States. AmJ Transplant 2004; 4: 905-913. (Pubitemid 38745589)
9. Quinlan SC, Landgren O, Morton LM, Engels EA. Hodgkin lymphoma among US solid organ transplant recipients. Transplantation 2010; 90: 1011-1015.
10. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009; 125: 1747-1754.
11. Opelz G, Daniel V, Naujokat C, Dohler B. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation 2009; 88: 962-967.
12. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514-1516. (Pubitemid 23362168)
13. Opelz G, Dohler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 222-230. (Pubitemid 38248525)
14. Quinlan SC, Pfeiffer RM, Morton LM, Engels EA. Risk factors for early-onset and late-onset posttransplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 2011; 86: 206-209.
15. Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: A UK Registry audit. Am J Transplant 2010; 10: 1889-1896.
16. International Association of Cancer Registries. In: Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, eds. Cancer Incidence in Five Continents, Vol. VIII. Lyons, France: IARC Press, 2002.
17. Goldstein MR, Mascitelli L, Pezzetta F. Angiotensin-receptor blockade, cancer, and concerns. Lancet Oncol 2010; 11: 817-818; author reply 821-822.
18. Alavanja MC. Biologic damage resulting from exposure to tobacco smoke and from radon: Implication for preventive interventions. Oncogene 2002; 21: 7365-7375. (Pubitemid 35305594)